Ad
related to: cetuximab- ERBITUX® (cetuximab)
HCPs View Prescribing, Dosing, &
Important Safety Information Here.
- Patient Self-Care Kit
Skin & Nail Care Info. Learn How to
Order The Patient Self Care Kit.
- Financial Assistance Info
See If Your Patients Are Eligible
For Our Reimbursement Program.
- Dose Modification Info
View Dosing Info Related to Side
Effects Of ERBITUX® (cetuximab).
- ERBITUX® (cetuximab)
Search results
Results From The WOW.Com Content Network
Cetuximab, sold under the brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer and head and neck cancer. [2] Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion .
Cetuximab is the first-line therapy for Ménétrier disease. [2] Cetuximab is a monoclonal antibody against epidermal growth factor receptor (EGFR), and has been shown to be effective in treating Ménétrier disease. [9] Several medications have been used in the treatment of the condition, with variable efficacy.
As of 2012, it was known that emergence of KRAS mutations was a frequent driver of acquired resistance to cetuximab anti-EGFR therapy in colorectal cancers. The emergence of KRAS mutant clones can be detected non-invasively [how?] months before radiographic progression.
Another avenue for novel anti-cancer therapies is re-engineering some of the currently used conventional antibodies like trastuzumab (targeting HER2/neu), cetuximab and panitumumab (both targeting the EGF receptor), using the BiTE approach. [28] As of 2009, BiTEs against CD66e and EphA2 are being developed as well. [29]
Cetuximab target the epidermal growth factor receptor . It is approved for use in the treatment of metastatic colorectal cancer [25] [26] and squamous cell carcinoma of the head and neck. [27] [28] Panitumumab also targets the EGFR. It is approved for the use in the treatment of metastatic colorectal cancer.
[30] [8] Skin and basophil activation tests with cetuximab are the most sensitive, but high costs limit their use. [31] In certain instances in which a person does not present with the typical symptoms and history of alpha-gal syndrome but is found to have elevated alpha-gal IgE levels, improvement with avoidance of red meat can be diagnostic ...
In July 2009, the FDA updated the labels of two anti-EGFR monoclonal antibody drugs (panitumumab and cetuximab) indicated for the treatment of metastatic colorectal cancer to include information about KRAS mutations. [14] This was the result of a study, which demonstrated lack of benefit with Panitumumab in patients who carried NRAS mutations. [6]
It directs cell fate decision relating to cell growth, survival and, differentiation. Development of matuzumab and other antibodies to the EGFR (for example cetuximab) as cancer therapeutics was motivated by observations that EGFR expression and/or signaling is frequently upregulated in cancer cells.
Ad
related to: cetuximab